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Modified Glucose-Insulin-Potassium Regimen Provides
Cardioprotection With Improved Tissue Perfusion in Patients
Undergoing Cardiopulmonary Bypass Surgery
Kun Zhao, MD, PhD;* Yue Zhang, MD, PhD;* Jia Li, MD, PhD;* Qin Cui, MD, PhD; Rong Zhao, MD, PhD; Wensheng Chen, MD, PhD;
Jincheng Liu, MD, PhD; Bijun Zhao, MD, PhD; Yi Wan, PhD; Xin-Liang Ma, MD, PhD; Shiqiang Yu, MD, PhD; Dinghua Yi, MD, PhD;
Feng Gao, MD, PhD
Background-—Laboratory studies demonstrate glucose-insulin-potassium (GIK) as a potent cardioprotective intervention, but
clinical trials have yielded mixed results, likely because of varying formulas and timing of GIK treatment and different clinical
settings. This study sought to evaluate the effects of modified GIK regimen given perioperatively with an insulin-glucose ratio of 1:3
in patients undergoing cardiopulmonary bypass surgery.
Methods and Results-—In this prospective, randomized, double-blinded trial with 930 patients referred for cardiac surgery with
cardiopulmonary bypass, GIK (200 g/L glucose, 66.7 U/L insulin, and 80 mmol/L KCl) or placebo treatment was administered
intravenously at 1 mL/kg per hour 10 minutes before anesthesia and continuously for 12.5 hours. The primary outcome was the
incidence of in-hospital major adverse cardiac events including all-cause death, low cardiac output syndrome, acute myocardial
infarction, cardiac arrest with successful resuscitation, congestive heart failure, and arrhythmia. GIK therapy reduced the incidence
of major adverse cardiac events and enhanced cardiac function recovery without increasing perioperative blood glucose compared
with the control group. Mechanistically, this treatment resulted in increased glucose uptake and less lactate excretion calculated
by the differences between arterial and coronary sinus, and increased phosphorylation of insulin receptor substrate-1 and protein
kinase B in the hearts of GIK-treated patients. Systemic blood lactate was also reduced in GIK-treated patients during
cardiopulmonary bypass surgery.
Conclusions-—A modified GIK regimen administered perioperatively reduces the incidence of in-hospital major adverse cardiac
events in patients undergoing cardiopulmonary bypass surgery. These benefits are likely a result of enhanced systemic tissue
perfusion and improved myocardial metabolism via activation of insulin signaling by GIK.
Clinical Trial Registration-—URL: clinicaltrials.gov. Identifier: NCT01516138. ( J Am Heart Assoc. 2020;9:e012376. DOI: 10.
1161/JAHA.119.012376.)
Key Words: cardiopulmonary bypass • insulin • cardiac surgery • tissue perfusion
M ounting experimental evidence has documented sig-nificant cardioprotection of glucose-insulin-potassium
(GIK) in ischemic hearts.1–4 However, clinical trials have not
consistently shown the beneficial effects of this therapy,
partly because of different formulas and administration timing
of GIK in these studies.5–9 The ratio of insulin to glucose in
previous GIK formulas was usually between 1:6 and 1:4, which
often led to significant elevation of blood glucose in GIK-
treated patients.5–9 Although the optimal level of glycemic
control in patients undergoing cardiac surgery as well as other
critically ill patients remains controversial,10–13 perioperative
hyperglycemia is generally associated with adverse outcome
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in patients undergoing cardiopulmonary bypass (CPB).12–14
Furthermore, our previous study demonstrated that hyper-
glycemia reduces the beneficial effects of GIK.15 Therefore,
we hypothesized that adjusting the insulin-glucose ratio of GIK
may avoid further increasing blood glucose and thus maximize
the protection of GIK for patients undergoing CPB.
The optimum timing of GIK infusion is another critical
issue. Strong experimental evidence pointed out that GIK
should be given early to be able to reach the ischemic
myocardium before reperfusion.16,17 The application of this
concept has been confirmed by several large clinical trials in
patients with acute myocardial infarction or acute coronary
syndromes (ACS).5,8,18 GIK given early ( 90 minutes) after
myocardial ischemia reduces the incidence of cardiac arrest
and in-hospital mortality,5 while late application (after reper-
fusion) of GIK fails to exert beneficial effects.8,18 Although this
treatment regimen greatly limits its application as an effective
treatment for acute myocardial infarction, preventive GIK
before myocardial ischemia is certainly achievable during
cardiac surgical procedure, which might slow the onset of
irreversible injury and result in the best recovery of myocar-
dial function via increased myocardial glycogen content
and production of glycolytic ATP during ischemia.13,19 There-
fore, this double-blinded, randomized, controlled clinical trial
was designed to test the effect of GIK with an insulin-glucose
ratio of 1:3, starting 10 minutes before anesthesia and lasting
for 12.5 hours, on the incidence of major adverse cardiac
events (MACE) in 930 patients undergoing cardiac surgery
with CPB.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request and
approval for the principal investigator.
Patient Population and Study Design
The study was approved by the Ethics Committee of Xijing
Hospital, Xian, China, registered with ClinicalTrials.gov (iden-
tifier: NCT01516138), and carried out in accordance with the
Declaration of Helsinki. Written, informed consent was
obtained from all patients or their legal surrogates before
study inclusion. A total of 2909 patients referred for cardiac
surgery with CPB at Xijing Hospital between February 2012
and March 2013 were screened for eligibility. Inclusion
criteria included age between 18 and 70 years, elective
cardiac surgery with first-time CPB, and left ventricular
ejection fraction ≥30%. Exclusion criteria were previous
cardiac surgery, emergent surgery, cardiac surgery without
the use of CPB, severe heart failure as defined by left
ventricular ejection fraction <30%, enrollment in another
clinical trial, pregnant or lactating woman or positive
pregnancy test, diabetes mellitus, severe renal insufficiency
or respiratory insufficiency, serious preoperative illness (eg,
sepsis, active systemic infection, and active malignancy
requiring treatment), history of drug abuse, bleeding diathesis
or coagulopathy, and subject who refuses blood transfusion.
Study Intervention
Subjects were randomly assigned to the GIK versus control
arm. Modified GIK included 20% glucose (200 g/L), 66.7 U/L
regular insulin (Novo Nordisk A/S, Bagsvaerd, Denmark), and
80 mmol/L KCl. The ratio of insulin to glucose is 1:3 in this
formula (while in most traditional GIK it is 1:5 or 1:6).
Intravenous administration started 10 minutes before anes-
thesia at a rate of 1 mL/kg per hour for 12.5 hours. Subjects
in the control arm received acetated Ringer’s solution (6.12 g/
L CH3COONa, 5.85 g/L NaCl, 0.3 g/L KCl, and 0.33 g/L
CaCl2) at the same rate for 12.5 hours. Blood glucose and
potassium were closely monitored during infusion by sampling
30 minutes before onset of CPB, every 20 minutes while on
CPB, and then every hour after CPB up to 12.5 hours with
protocol-based management of blood glucose and potassium.
All the subjects received the standard of care plus GIK or
control treatment.
Randomization
A computer-generated block randomization sequence was
used. Investigators were required to confirm patient eligibility.
Randomization was performed in the block size of 6 without
Clinical Perspective
What Is New?
• In this randomized, double-blind, and placebo-controlled
trial, a modified glucose-insulin-potassium regimen with an
insulin-glucose ratio of 1:3 exerted significant cardioprotec-
tion and reduced the incidence of in-hospital major adverse
cardiac events in patients undergoing cardiopulmonary
bypass surgery, without further increasing blood glucose
levels compared with control.
• These data also provided the first piece of direct evidence of
alleviated postoperative hyperlactemia and preserved renal
function by the modified glucose-insulin-potassium.
What Are the Clinical Implications?
• Our findings support the cardioprotection of the modified
glucose-insulin-potassium (insulin-glucose ratio 1:3) and
suggest that glucose-insulin-potassium could be part of the
perioperative medication in cardiopulmonary bypass sur-
gery, especially in developing countries, attributable to its
low cost and wide applicability.
DOI: 10.1161/JAHA.119.012376 Journal of the American Heart Association 2
Cardioprotection of GIK during CPB Zhao et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 6, 2020
taking into account any of the patient’s characteristics (such
as age or sex). Information was kept in a sealed envelope and
opened by a trial investigator at the time of patient
enrollment. Intervention and control drug infusion packets
were identical in appearance and contained no treatment-
identifying information. The interventions (GIK vs. balanced
salt solution) were blinded to surgeons, patients, and
assessors.
Anesthesia, Cardiopulmonary Bypass, and
Surgery
All patients received a standard anesthetic protocol compris-
ing sufentanil 0.5 to 1 lg/kg, midazolam 2 mg, etomidate
0.1 to 0.2 mg/kg, and rocuronium 0.6 to 0.8 mg/kg, and all
patients were fully heparinized (3 mg/kg) to achieve an
activated clotting time >400 seconds. Standard CPB was
established by experienced cardiac surgeons with the use of a
hollow-fiber oxygenator (Medtronic, Minneapolis, MN) and a
roller pump (Stockert-sc, Germany) with ascending aortic and
bicaval cannulations. During CPB, moderate hemodilution
(hematocrit 20–25%) with mild systemic hypothermia (30°–
32°C) was used. Cold blood antegrade perfusion was used for
cardioplegia in patients. The crystalloid high-potassium solu-
tion contained (in mmol/L): 140 Na+, 75 K+,16 Mg2+, 1.2
Ca2+, 104 Cl–, 20 HCO3
–, 10 glucose, and 0.7 lidocaine (pH
7.6–7.7). After aortic cross clamping, the cardioplegic arrest
was obtained with the 4:1 blood/crystalloid high-potassium
solution antegrade infusion at 4°C, with a flow rate of 300–
330 mL/min for 4 minutes. For patients without aortic valve
regurgitation, cardioplegia was infused through a double-
lumen needle in the ascending aorta for antegrade adminis-
tration. For those patients with aortic regurgitation, the aorta
was opened promptly after the cross clamp was applied, the
left and right coronary artery ostia were cannulated, and the
cold blood cardioplegia was delivered though a Y bifurcated
catheter. This procedure was reproduced every 25 to 30
minutes to maintain cardioplegia. All operations were per-
formed by experienced cardiac surgeons using standard
techniques; type of surgery and procedural strategies were
applied at the surgeon’s discretion. All patients were admitted
postoperatively into the cardiac intensive care unit (ICU) for
further treatment.
Outcome Measures
The primary outcome measurement was composite in-hospital
MACE that included all-cause death, low cardiac output
syndrome, acute myocardial infarction, cardiac arrest with
successful resuscitation, congestive heart failure and arrhyth-
mia (ie, postoperative atrial fibrillation), supraventricular
tachycardia, nonsustained ventricular tachycardia, and
ventricular fibrillation. Low cardiac output syndrome was
defined as cardiac index <2.2 L/min per m2 or the need of
intra-aortic balloon pumping or infusion of vasoactive agents
for ≥30 minutes to maintain systolic blood pressure at ≥90
mm Hg. Acute myocardial infarction, assessed by an inde-
pendent blinded cardiologist, was defined as new Q waves in
an ECG or creatine kinase–myocardial bands (CK-MB) at ≥5
times the upper normal limit with classic angina symptoms.
Congestive heart failure was defined as physician documen-
tation or report of clinical symptoms of heart failure,
described as unusual dyspnea on light exertion, recurrent
dyspnea occurring in the supine position, fluid retention; or
jugular venous distention, pulmonary edema on physical
examination, or pulmonary edema on chest roentgenogram.
Postoperative atrial fibrillation was defined as new-onset atrial
fibrillation (AF) requiring treatments; that is, AF persisted for
>60 minutes or recurrent episodes of AF 48 hours after
surgery. Patients with a history of AF were excluded.
Secondary outcomes included in-hospital renal complications,
redo operation, stroke, infection, prolonged ventilation, and
stay in the ICU and hospital, as well as mortality during 3-year
follow-up. Renal complications were defined by an increase in
the serum creatinine level by a factor of ≥2 from baseline, a
urine output of no more than 0.5 mL/kg per hour for 12
hours, or the use of acute hemodialysis. Infection was culture-
proven septicemia or pneumonia. Prolonged ventilation was
defined as ventilatory support for >24 hours. Left ventricular
ejection fraction at 24 hours after surgery and before patient
discharge and CK-MB during the 48 hours after surgery were
also prespecified outcome measures.
Measurements
Transthoracic 2-dimensional Doppler echocardiography
(M-mode) was carried out on admission, 24 hours after the
surgery, and immediately before discharge. The measure-
ments reflect the averages over 3 to 5 cycles based on the
American Society of Echocardiography Guidelines. Left ven-
tricular ejection fraction was assessed using the biplane
Simpson method.
Arterial blood samples were collected before the surgery
(baseline); 5 minutes after commencing CPB; 5 minutes after
aortic cross clamp (ACC); 5 minutes after ACC removal; and 1,
6, 12, 24, and 48 hours after completion of the surgery. Blood
glucose and lactate concentration were determined by using a
standard blood gas and electrolyte analyzer (GEM Premier
3000, Instrumentation Laboratory, Bedford, MA). CK-MB,
cardiac troponin I, blood urea nitrogen and creatinine at
preoperation and 24 and 48 hours after surgery were
measured by using an Access AccuTnI assay system (Beck-
man-Coulter, Fullerton, CA). The total released amounts of CK-
MB, cardiac troponin I, blood urea nitrogen, and creatinine
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were represented as 0- to 48-hour area under the curve after
surgery.
To evaluate myocardial extraction/excretion of glucose,
oxygen, and lactate, blood samples were collected simulta-
neously from the radial artery and the coronary sinus
immediately before ACC and at 5 minutes after ACC removal.
Coronary sinus samples were obtained from a coronary sinus
cardioplegia cannula, and the number of patients who had
these measurements was 16 in GIK and 20 in control.
Myocardial extraction/excretion was calculated as (arterial
concentration  coronary sinus concentration) / arterial
concentration 9 100%. Oxygen content in blood samples
was calculated using the formula: oxygen content = 1.39
9 Hb 9 O2 Sat.
20 For lactate, a positive value indicates
lactate uptake, whereas a negative value indicates lactate
excretion.21
Western Blotting and Transmission Electron
Microscopy
Left ventricular biopsies were obtained from patients (10 in
GIK and 10 in control) undergoing aortic valvular replacement
or double valvular replacement with concomitant septal
myectomy caused by left ventricular outflow tract obstruction,
having resection of fibrous-muscular attachments between
papillary muscle and ventricular septum as an indispensable
procedure for surgery. All these patients had signed to agree
to surgical specimen disposal before surgery. Biopsies were
obtained 15 minutes after ACC removal and immediately
snap-frozen in liquid nitrogen for western blotting with
antibodies against Akt (protein kinase B), phospho-Akt
(Ser473) (Cell Signaling Technology, Danvers, MA), insulin
receptor substrate-1 (IRS-1), phospho-IRS-1 (Tyr612, Milli-
pore), or glyceraldehyde 3-phosphate dehydrogenase (Abcam,
Cambridge, UK). Some cardiac biopsies were fixed in
Karnovsky’s reagent (0.1 mol/L sodium cacodylate with 2%
paraformaldehyde and 2.0% glutaraldehyde, pH 7.4), postfixed
in 2% osmium tetroxide, dehydrated in ethanol in propylene
oxide, and embedded in Poly/Bed812 (Polysciences, War-
rington, PA). Semithin sections (2 lm) were stained with
toluidine blue (Sigma-Aldrich, St Louis, MO), and thin sections
(60 nm) were obtained with NOVA ultratome (LKB Vertriebs
GmbH, Vienna, Austria), stained with lead citrate and
examined with a Tecnai G2 transmission electron microscope
(FEI, Hillsboro, OR). Patients with cardiac biopsies were
excluded from the biomarker evaluations.
Statistical Analysis
Power analysis indicated that at a level of 0.05 (2-tailed), an
evaluable sample of 815 subjects would provide 85% power to
detect a relative 10% reduction in the primary end point for
GIK versus control from 40% to 30%6,9. At least 896 subjects
would be required for randomization to account for an
anticipated attrition and patients withdrawing consent.
All analyses were conducted using the intent-to-treat cohort,
composed of all randomized participants. Continuous variables
were presented as mean plus/minus SD and analyzed with
Student’s t-test if normally distributed. Continuous variables
not following normal distribution were presented as medians
and interquartile range, and analyzed with Mann-Whitney
U-test. Categorical variables were analyzed with chi-square or
Fisher’s exact test. The primary outcome measure was
expressed as odds ratio with 95% CI. Three-year mortality was
analyzed by the Kaplan–Meiermethod and compared by the log-
rank test. Blood glucose and lactate levels over time were
analyzed with the use of mixed models, which included
surgeons and study subjects as random effects. Multiple
testing was adjusted with Bonferroni’s method. All analyses
were performed with SPSS 12.0 (SPSS Inc, Chicago, IL).
Statistical significance was set at P<0.05 (2-tailed).
Results
Study Population and Baseline Characteristics
As shown in Figure 1, a total of 930 patients were eligible for
randomization (n=465 per arm). Demographics were compa-
rable between the 2 arms (Table 1). The 2 groups did not
significantly differ with respect to smoking, hypertension,
previous myocardial infarction, and preoperative medications
including b-blockers, digitalis glycosides, and statins. The
mean European System for Cardiac Operative Risk Evaluation
score was 4.191.77 in the GIK arm and 4.241.77 in the
control arm (P=0.699).
The majority of patients undergoing cardiac surgery in this
study had valvular heart diseases (52.3% in GIK, 51.6% in
control). Congenital heart diseases took the second place
(37.4% in GIK, 37.4% in control). The percentage of subjects
receiving coronary artery bypass grafting surgery was com-
parably low (7.1% in GIK, 7.3% in control). Detailed surgery
classification is described in Table 2. In summary, there was
balance in the type of cardiac surgery and in the composition
of the background diseases between the GIK and control
arms. Furthermore, the 2 arms did not differ in operation time,
cross-clamping time, and CPB time.
Outcomes
The data set for primary measure included all 930 subjects. As
shown in Table 3, the rate of in-hospital MACE was significantly
lower in the GIK arm. GIK therapy significantly reduced the
incidence of low cardiac output syndrome and congestive heart
failure. GIK also decreased the incidence of new-onset AF and
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nonsustained supraventricular tachycardia but not ventricular
fibrillation. Incidence of cardiac arrest with successful resus-
citation and acute myocardial infarction did not differ between
the 2 arms.
Twenty of the 930 patients died in hospital (1.7% inGIK versus
2.6% in control; odds ratio, 0.66; 95% CI, 0.27–1.63; P=0.366).
Nine patients died from multiple-organ failure (5 in GIK, 4 in
control). Eleven patients died from acute cardiovascular collapse
(4 in GIK, 7 in control). No further deaths were observed during
30 days of follow-up. During 3-year follow-up, 37 patients could
not be contacted (19 in control, 18 in GIK), 3 patients withdrew
consent (2 in control, 1 in GIK), and 12 patients died (7 in control,
5 inGIK). No significant difference inmortality was observed at 3-
year follow-up (2.8% in GIK versus 4.1% in control; P=0.278).
Long-term follow-up is ongoing to determine whether a modified
GIK regimen improves patient prognosis.
Secondary outcomes are shown in Table 4. The incidence of
renal complications in patients undergoing cardiac surgery with
CPB was significantly lower in the GIK arm. Hospital stay did not
differ between the 2 arms, but stay in the ICU was significantly
shorter in the GIK arm. The number of patients requiring
intensive care for >3 days was also markedly lower in the GIK
arm. Time on mechanical ventilation support did not differ
between the 2 arms; however, the number of patients on
ventilation support for >24 hours was significantly lower in the
GIK arm. There was no statistically significant difference in the
proportion of patients who required redo operation or in the rate
of postoperative stroke and sepsis between the 2 arms.
Patients listed for cardiac surgery with CPB
Assessed for eligibility n=2909
n=1979  Did not meet criteria
n=1341  Age < 18 years or > 70 years  
n=89    Emergent surgery
n=12    Previous cardiac surgery
n=80    Diabetes mellitus
n=4     Severe renal insufficiency  
n=21    Severe respiratory insufficiency 
n=42    LVEF < 30%
n=8     Heart transplantation
n=309   Enrollment in other trials
n=73    Refused trial
Randomized 1:1 n=930
465 Allocated to receive control 465 Allocated to receive GIK 
465 included in the primary outcome 
and 30-day mortality analysis
465 included in the primary outcome 
and 30-day mortality analysis
19 did not attend follow-up
2 withdrew consent 
18 did not attend follow-up 
1 withdrew consent
444 included in the 180-day and 
3-year mortality analysis 
446 included in the 180-day and 
3-year mortality analysis 
Figure 1. Number of patients assessed, enrolled, and randomized in the trial. CPB indicates
cardiopulmonary bypass; GIK, glucose-insulin-potassium; LVEF, left ventricular ejection fraction.
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Blood Glucose and Lactate Levels
Blood glucose gradually increased after CPB and reached a
peak at 6 hours after surgery in both arms (Figure 2A).
Neither the entire temporal profile of blood glucose nor the
peak glucose level differed between the 2 arms. Hypo-
glycemia (defined as a blood glucose level of ≤40 mg/dL)
occurred in 3 patients in the GIK arm and 1 patient in the
control arm. Similarly, blood lactate rose slowly during CPB
and shot up at 6 hours after surgery in both arms (Figure 2B).
However, GIK therapy significantly reduced lactate levels at 1
hour (3.52.0 versus 4.02.1 mmol/L in control; P<0.001),
6 hours (5.03.1 versus 6.54.0 mmol/L in control;
P<0.001), and 12 hours (4.62.8 versus 5.63.2 mmol/L
in control; P<0.001) after surgery.
Postoperative LVEF
As shown in Table 1, the preoperative LVEF was comparable
between the 2 arms. The number of patients who had a >50%
LVEF was similar between the 2 arms. A significant decline of
LVEF was observed at 24 hours after operation. As shown in
Table 5, compared with the control arm, the number of
Table 1. Preoperative and Intraoperative Data
Variables Control (n=465) GIK (n=465) P Value
Age, meanSD, y 42.513.5 42.3 13.6 0.565
BMI, meanSD, kg/m2 23.84.6 23.4 4.2 0.446
Male sex 206 (44.3) 199 (42.8) 0.643
Current smoker 179 (38.5) 164 (35.3) 0.308
Hypertension 36 (7.7) 45 (9.9) 0.295
Previous MI 9 (1.9) 11 (2.4) 0.651
COPD 28 (6.0) 22 (4.7) 0.383
Preoperative b-blockers 58 (12.5) 57 (12.3) 0.921
Preoperative
digitalis glycosides
133 (28.6) 145 (41.6) 0.390
Preoperative statins 27 (5.8) 25 (0.54) 0.775
Logistic EuroSCORE,
meanSD
4.241.77 4.191.77 0.699
NYHA class
II 333 (71.6) 320 (68.8) 0.351
III/IV 132 (28.4) 145 (31.2) 0.351
LVEF, meanSD, % 54.98.2 55.07.4 0.840
LVEF category
Moderate (30–50%) 124 (26.7) 116 (24.5) 0.549
Good (>50%) 341 (73.3) 349 (75.1) 0.549
Type of surgery
Congenital 174 (37.4) 174 (37.4) >0.999
Valve 240 (51.6) 243 (52.3) 0.844
CABG only 34 (7.3) 33 (7.1) 0.899
Cardiac myxoma 17 (3.7) 15 (3.2) 0.719
Operation time,
meanSD, min
191.480.5 189.674.0 0.721
ACC time,
meanSD, min
51.531.2 50.630.4 0.676
CPB time,
meanSD, min
106.548.0 103.346.7 0.313
EuroSCORE is the European System for Cardiac Operative Risk evaluation. Values are
numbers (percentages) or mean SD. ACC indicates aortic cross clamp; BMI indicates
body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive
pulmonary disease; CPB, cardiopulmonary bypass; GIK, glucose-insulin-potassium; LVEF,
left ventricular ejective fraction; NYHA, New York Heart Association; previous MI,
myocardial infarction within 90 days.
Table 2. Surgery Classification of the Patients
Surgery
Control
(n=465),
n (%)
GIK (n=465),
n (%) P Value
Valve surgery* 240 (51.6) 243 (52.3) 0.844
AVR with or
without CABG
56 (12.0) 58 (12.5) 0.842
BENTALL 10 (2.2) 9 (1.9) 0.817
DVR 60 (12.9) 69 (14.8) 0.393
AVR +TVP 2 (0.4) 0 (0.0) 0.250
DVR +TVP 2 (0.4) 2 (0.4) >0.999
MVR 93 (20.0) 85 (18.3) 0.505
MVR+TVP 14 (3.0) 15 (3.2) 0.850
TVR 3 (0.6) 5 (1.1) 0.732
Congenital 174 (37.4) 174 (37.4) >0.999
Noncyanotic
heart disease
156 (33.5) 159 (34.2) 0.835
Atrial septal repair† 56 (12.0) 52 (11.2) 0.682
Ventricular
septal repair‡
100 (21.5) 107 (23.0) 0.581
Cyanotic heart disease 18 (3.9) 15 (3.2) 0.595
Tetralogy of Fallot repair 8 (1.7) 7 (1.5) 0.795
TAPVC/PAPVC repair 10 (2.2) 8 (1.7) 0.634
CABG 34 (7.3) 33 (7.1) 0.899
Resection of
cardiac myxoma
17 (3.7) 15 (3.2) 0.719
AVR indicates aortic valvular replacement; BENTALL, aortic valvular replacement with
root of the ascending aorta replacement; CABG, coronary artery bypass grafting; DVR,
double valvular replacement; GIK, glucose-insulin-potassium; MVR, mitral valvular
replacement/repair; TAPVC/PAPVC, total/partial anomalous pulmonary venous
connection; TVP, tricuspid valve repair; TVR, tricuspid valve replacement.
*Valve surgery indicates valvular replacement or repair due to congenital, rheumatic, or
infective valvular diseases.
†Atrial septal repair indicates atrial septal repair with or without patent ductus arteriosus
and partial endocardial cushion defect.
‡Ventricularseptal repair includesventricularseptal repairwithorwithoutatrialseptal repair,
patent ductus arteriosus, pulmonary stenosis, and rupture aneurysm of aortic sinus.
DOI: 10.1161/JAHA.119.012376 Journal of the American Heart Association 6
Cardioprotection of GIK during CPB Zhao et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 6, 2020
subjects with a >50% LVEF significantly increased in the GIK
arm 24 hours after operation and before discharge. In
addition, the numbers of subjects with LVEF between 30%
and 50% went down in the GIK arm. The number of patients
with a <30% postoperative LVEF was similar between the 2
arms. Patients who died in hospital were considered to have
an LVEF below 30%.
Cardiac and Renal Biomarkers
Preoperative CK-MB and cardiac troponin I levels were
comparable between the GIK and control arms (Table 6).
Patients with cardiac biopsies were excluded from the
biomarker evaluations (10 in GIK and 10 in control). The
median area under the curve from 0 to 48 hours after
surgery for CK-MB was significantly lower in (1596 [1167–
2133] U/L versus 1680 [1260–2304] U/L in control;
P=0.014). Similar results were found for the 0- to 48-hour
area under the curve for cardiac troponin I measurements
(166 [88–288] ng/mL in GIK versus 190 [114–335] ng/mL
in control; P=0.01). Preoperative blood urea nitrogen and
creatinine levels were comparable between the 2 arms.
However, the area under the curve from 0 to 48 hours after
surgery for both creatinine (5064 [4404–5904] versus 5323
[4500–6192] lmol/L in control; P=0.017) and blood urea
nitrogen (396 [324–492] U/L versus 420 [347–516] mmol/
L in control; P=0.003) decreased significantly in GIK-treated
patients.
Regulation by GIK of Myocardial Glucose
Metabolism
Myocardial glucose metabolism was evaluated by measure-
ment of arterial and coronary sinus concentrations of glucose,
oxygen, and lactate immediately before ACC and 5 minutes
after ACC removal in 36 patients (20 GIK and 16 control
subjects). As shown in Figure 2C, GIK increased myocardial
glucose uptake before ACC as well as after the release of
ACC. These increases resulted in more abundant glycogen
store in the hearts of GIK-treated patients than those in the
controls by electron microscopic analysis (Figure 2F). In
Table 3. Primary Outcome of the Patients
Variables Control (n=465) GIK (n=465) OR (95% CI) P Value
Major adverse cardiac events 177 (38.1) 120 (25.8) 0.57 (0.43–0.75) <0.001
In-hospital mortality 12 (2.6) 8 (1.7) 0.66 (0.27–1.63) 0.366
Low cardiac output syndrome 97 (20.9) 73 (15.7) 0.71 (0.51–0.99) 0.042
Acute myocardial infarction 1 (0.2) 1 (0.2) 1.00 (0.06–16.04) >0.999
Cardiac arrest with successful resuscitation 4 (0.9) 3 (0.6) 0.75 (0.17–3.36) 0.704
Congestive heart failure 26 (5.6) 10 (2.2) 0.37 (0.18–0.78) 0.007
Arrhythmia
POAF 56 (12.0) 29 (6.2) 0.47 (0.30–0.78) 0.002
SVT 29 (6.2) 14 (3.0) 0.47 (0.24–0.90) 0.019
NSVT 18 (3.9) 7 (1.5) 0.39 (0.16–0.94) 0.026
VF 9 (1.9) 6 (1.3) 0.66 (0.23–1.88) 0.435
Values are numbers (percentages). Composite adverse cardiac events included all-cause mortality in hospital, low cardiac output syndrome, acute myocardial infarction, cardiac arrest with
successful resuscitation, congestive heart failure, and arrhythmia. Low cardiac outcome syndrome was defined as cardiac index <2.2 L/(min.m2) or need of intra-aortic balloon pumping or
infusion of epinephrine, milrinone, or dobutamine to maintain systolic blood pressure ≥90 mm Hg. Acute myocardial infarction, assessed by an independent blinded cardiologist, was
defined as new Q waves in ECG or CK-MB at ≥5 times the upper normal limit with classic angina symptoms. Congestive heart failure was defined as physician documentation or report of
the clinical symptoms of heart failure, described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or jugular venous distention,
pulmonary edema on physical examination, or pulmonary edema on chest roentgenogram. Arrhythmia included POAF, SVT, NSVT, and VF. POAF was defined as new-onset atrial fibrillation
requiring treatments; that is, atrial fibrillation persisted for >60 minutes or recurrent episodes of atrial fibrillation 48 hours after surgery. GIK indicates glucose-insulin-potassium; NSVT,
nonsustained ventricular tachycardia; OR, odds ratio; POAF, postoperative atrial fibrillation; SVT, supraventricular tachycardia; VF, ventricular fibrillation.
Table 4. Secondary Outcomes of the Patients
Variables Control (n=465) GIK (n=465) P Value
Renal complications 41 (8.8) 23 (4.9) 0.020
Redo operation 18 (3.9) 20 (4.3) 0.740
Stroke 6 (1.3) 3 (0.6) 0.503
Infection 18 (3.9) 15 (3.2) 0.595
Length of stay in ICU, d 3 (2–4) 3 (2–3) 0.005
Length of stay in ICU >3 d 119 (25.6) 88 (18.9) 0.015
Mechanical ventilation, h 21 (12–24) 20 (15–24) 0.023
Prolonged ventilation >24 h 115 (24.7) 81 (17.4) 0.006
Values are numbers (percentages) or medians and interquartile range. Renal complications
was defined by an increase in the serum creatinine level by a factor of ≥2 from baseline, a
urine output of no more than 0.5 mL/kg per hour for 12 hours, or the use of acute
hemodialysis. GIK indicates glucose-insulin-potassium; ICU, intensive care unit.
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addition, myocardial oxygen extraction did not differ between
the 2 arms at either time point (P=0.082 and P=0.900,
respectively; Figure 2E). After commencing CPB but before
ACC, lactate was excreted by the heart in the control arm but
extracted by the heart in the GIK arm (Figure 2D). At 5
minutes after reperfusion, lactate excretion was significantly
lower in the GIK arm.
IRS-1 and Akt phosphorylation were studied in cardiac
biopsies from 20 patients (10 GIK and 10 control subjects). As
shown in Figure 3, there was a 1.8-fold increase in the ratio of
phospho-IRS-1 to IRS and a 2.3-fold increase in the ratio of
phospho-Akt to total Akt in GIK-treated patients, suggesting that
activation of insulin signaling may contribute to regulation of
myocardial glucose metabolism by GIK therapy described above.
Discussion
We have made 3 major observations in the present study.
First, this is the first trial to test the effectiveness of a
modified GIK regimen in which insulin-glucose ratio is
adjusted to 1:3 and GIK is administered perioperatively. Second,
this is by far the largest GIK surgical trial, with 930 patients
Figure 2. Regulation of glucose metabolism by GIK. Blood glucose (A) and lactate levels (B) between
the GIK and control arms before the surgery (baseline), 5 minutes after commencing CPB, 5 minutes
afterACC), 5 minutes after ACC removal and 1, 6, 12, 24, and 48 hours after surgery. Values are
meanSD for all the patients in both arms. **P<0.01 vs control. Percentage of myocardial extraction/
excretion of glucose (C), lactate (D), and oxygen (E) immediately before ACC and 5 minutes after ACC
removal. Positive value indicates myocardial extraction, whereas negative indicates myocardial
excretion. Values are meanSD for 16 patients in the GIK arm and 20 patients in the control arm.
(F) Glycogen abundance in cardiac biopsies performed 15 minutes after ACC removal by transmission
electron micrograph. ACC indicates aortic cross clamp; CPB, cardiopulmonary bypass; GIK, glucose-
insulin-potassium.
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undergoing CPB surgery included. Third, we found that GIK
significantly reduced the incidence of in-hospital MACE in
patients with CPB. Mechanistically, this treatment improved
myocardial metabolic state as manifested by increased glucose
uptake, more glycogen stores, and less lactate excretion in GIK-
treated patients. Our data also present the first piece of direct
evidence of alleviated postoperative hyperlactemia and pre-
served renal function by GIK. This modified GIK therapy also
decreased the incidences of prolonged ICU stay and extended
ventilator support in CPB patients.
Since the first application of GIK in ischemic heart disease
in the 1960s, GIK therapy has gone through altering periods
of varying attention.1,22,23 Previous clinical trials about GIK
focused largely on the management of acute coronary
syndrome,5,7 while only few studies were specific to the
setting of cardiac surgery with small population and most
studies were conducted in the setting of coronary artery
bypass grafting surgery.6,22–24 In contrast, the majority of
patients involved in this study underwent valve surgery or
congenital repair surgery because of high prevalence of these
2 heart diseases in the northwest of China. Our results
showed that GIK improved cardiac hemodynamic perfor-
mance, as manifested by lower incidence of low cardiac
outcome syndrome, reduced need for inotropic support, and
improved LVEF after surgery, which was in agreement with
previous reports about GIK6. However, compared with previ-
ous GIK formulas with low insulin-glucose ratios,5,6,8 GIK with
an insulin-glucose ratio of 1:3 did not further elevate blood
glucose, indicating a better glycemic control of this modified
regimen in patients with cardiac surgery. Although blood
glucose gradually increased during CPB and exceeded
200 mg/dL at 6 hours after operation in both GIK and
control arms, our data still demonstrate the benefits of GIK
infusion in CPB surgery, suggesting the direct cardioprotective
effects of insulin in addition to its preventive effects against
hyperglycemia.13,15
During ischemia and reperfusion, the heart breaks down
endogenous glycogen stores and/or increases its extraction
of circulating glucose to maintain glycolytic flux, which is
critical for preserving cellular viability.1 In this trial, GIK
therapy was started about 10 minutes before general
anesthesia, which resulted in higher glucose uptake in the
heart even before ischemia and consequently increased
myocardial glycogen store. Sustained GIK infusion during
ischemia continued to enhance myocardial glycolytic flux. All
these actions increase production of glycolytic ATP, prevent
total cellular ATP levels from falling below a critical threshold,
and thus slow the onset of irreversible myocardial injury.
Furthermore, stimulation of glucose metabolism by GIK
Table 5. Postoperative LVEF of the Patients
Variables Control n=465 GIK n=465 P Value
Postoperative 24 h
Poor (<30%) 5 (1.1) 5 (1.1) >0.999
Moderate (30%–50%) 300 (64.5) 269 (57.8) 0.037
Good (>50%) 160 (34.4) 191 (41.1) 0.036
Before discharge
Poor (<30%) 9 (1.9) 7 (1.5) 0.608
Moderate (30%–50%) 135 (29.0) 99 (21.3) 0.007
Good (>50%) 321 (69.0) 359 (77.2) 0.005
Values are numbers (percentages). GIK indicates glucose-insulin-potassium; LVEF, left
ventricular ejection fraction.
Table 6. Cardiac and Renal Biomarkers
Variables Control GIK P Value
CK-MB, median (IQR), U/L n=455 n=455
Preoperative 11.2 (8.4–14.4) 11.0 (8.0–14.0) 0.766
Postoperative 0–48 h AUC 1680 (1260–2304) 1572 (1164–2112) 0.002
cTnI, median (IQR), ng/mL n=455 n=455
Preoperative 0.01 (0.01–0.02) 0.02 (0.02–0.02) 0.121
Postoperative 0–48 h AUC 193 (114–335) 167 (91–288) 0.012
Cr, median (IQR), lmol/L n=465 n=465
Preoperative 88.5 (80–98) 89 (81–98) 0.646
Postoperative 0–48 h AUC 5323 (4500–6192) 5064 (4404–5904) 0.017
BUN, median (IQR), mmol/L n=465 n=465
Preoperative 5 (4–6) 5 (4–6) 0.140
Postoperative 0–48 h AUC 420 (347–516) 396 (324–492) 0.003
AUC indicates area under the curve; BUN, blood urea nitrogen; CK-MB, creatine kinase–myocardial bands; Cr, creatinine; cTnI, cardiac troponin I; GIK, glucose-insulin-potassium; IQR,
interquartile range.
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improves oxygen use efficiency during ischemia because the
oxidation of glucose as substrate is more efficient than fatty
acids.1,25 Our findings that preserved contractile function
without increase of myocardial oxygen extraction in the GIK
arm suggest that GIK could improve myocardial performance
without affecting oxygen consumption.
Myocardial lactate release has been advocated as a
negative end point in clinical trials evaluating perioperative
myocardial protection. Rao et al26 observed that aortic cross-
clamping induces anaerobic myocardial metabolism with a net
release of lactate. Persistent lactate release during reperfu-
sion suggests a delayed recovery of normal aerobic
metabolism and may lead to depressed myocardial function.
In this trial, GIK therapy reduced myocardial lactate release at
early reperfusion, suggesting an improved anaerobic metabo-
lism during ischemia or a more rapid recovery of aerobic
metabolism during reperfusion. This may contribute to
myocardial protection and functional recovery observed in
GIK-treated patients. However, we only used the concentra-
tion differences between arterial and coronary sinus blood to
evaluate myocardial metabolism. The actual substrate and
oxygen uptake or release is also determined by blood flow, so
great caution should be exercised in the interpretation of
these data.
Blood lactate is a sensitive marker of the magnitude of
anaerobic metabolism and tissue oxygen deficit during
cardiac surgery with CPB.27,28 Tissue hypoperfusion with
lactic acidosis during CPB may occur despite normal blood
gas concentrations.29 In high-risk patients undergoing general
surgery, there is a positive correlation between the estimated
intraoperative oxygen deficit and postoperative lactate con-
centration.30 Hyperlactemia during CPB has been proposed to
be a potential marker for postoperative morbidity and
mortality.27 Change in lactate over time can be a reliable
marker of a response to therapeutic interventions and
subsequent outcomes.30 We observed a significant reduction
of systemic blood lactate in GIK-treated patients, which
suggests improved tissue perfusion during CPB surgery and
potentially contributes to better outcomes such as decreased
postoperative complications and shorter stay in the ICU.
Study Limitations
First, the current study was conducted in a single center of
China and predominantly selected a Han Chinese population
of patients with valvular heart diseases and congenital heart
diseases. The prevalence of these 2 diseases is high, and the
number of cardiac surgical procedures is growing in China,31
while the percentage of coronary artery bypass grafting
surgery is comparably low because most patients with
coronary artery diseases prefer percutaneous coronary inter-
vention, as it is less invasive and less costly. Second,
considering the “younger and healthier” patients enrolled in
this study (mean age, 42 years; mean body mass index, 23
kg/m2) as compared with the typical cardiac surgery patient
profiles reported in the Western literature, and the absence of
diabetes mellitus in this trial, our results should be interpreted
with caution. Further studies are needed to evaluate the
Figure 3. Activation of insulin signaling in the hearts of GIK-treated patients. Representative western
blots and quantification of IRS-1, Tyr phosphorylated IRS-1, Akt, Ser473 phosphorylated Akt in cardiac
biopsies. Each bar denotes meanSD intensities quantified by densitometric analysis of the
immunoblots. n=10 per group. Akt indicates protein kinase 1; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; GIK, glucose-insulin-potassium; IRS-1, insulin receptor substrate 1; p-Akt, phospho-
Akt; p-IRS-1, phospho-IRS-1.
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safety and effectiveness of a modified GIK regimen in elderly
patients and those with diabetes mellitus.
Conclusions
Our modified GIK regimen (insulin-glucose ratio 1:3) adminis-
tered perioperatively reduces the incidence ofMACE in patients
undergoing CPB surgery. These benefits are likely the result of
enhanced systemic tissue perfusion and improved myocardial
metabolism via activation of insulin signaling by GIK.
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